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ABSTRACT  
Objective: To develop a rapid, sensitive, accurate, precise and linear Reverse-Phase High-Performance Liquid Chromatographic (RP-HPLC) method 
and validate as per ICH guidelines for the quantitative estimation of Pazopanib Hydrochloride (PBH) drug substance along with two process 
impurities.  
Methods: The developed method uses a reverse phase Zorbax RP18 column (50 mm×4.6 mm; 5.0 µm), a mobile phase of 0.015M Potassium 
dihydrogen orthophosphate buffer (pH 3.0 with orthophosphoric acid) and methanol in the proportion of 16:84 v/v. The mobile phase was set at a 
flow rate of 0.8 ml/min and the volume injected was 10μl for every injection. The detection wavelength was set at 215 nm. 
Results: Newly developed method resulted in eluting the two process impurities of PBH at 2.998 and 23.548 min respectively. The detection limits 
(LOD) were about 0.0061 and 0.0062 mg/ml and quantitation limit (LOQ) were about 0.024 and 0.021 mg/ml. The relative standard deviation was 
found to be 0.78 % and 1.38 % respectively for the two process impurities of PBH. The % recovery of the PBH impurities ranged from 97.3 to 100 % 
and 94.0 % to 99.0 % respectively. 
Conclusion: Two new process impurities of PBH drug substance were determined and characterized by newly developed RP-HPLC method, and 
identified using LC–MS technique. Proposed structures of these impurities were confirmed by structural elucidation using NMR techniques. The 
HPLC method was validated as per ICH guidelines. The newly developed reversed-phase liquid chromatographic method was found to be accurate, 
simple, sensitive and selective. It was also found to exhibit excellent resolution for the two process impurities and the PBH drug substance 
indicating high sensitivity and selectivity of the validated method. 
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INTRODUCTION  
Pazopanib Hydrochloride (PBH) chemically known as 5-[[4-[2, 3-
dimethyl-2H-indazol-6yl) methylamino]-2-pyrimidinyl] amino]-2-




Fig. 1: Structure of Pazopanib Hydrochloride drug substance 
 
It is potent and selective multi-targeted tyrosine receptor inhibitor 
of Vascular Endothelial Growth Factor Receptor-1 (VEGFR-1), 
VEGFR-2, VEGFR-3, Platelet Derived Growth Factor Receptor 
(PDGFR-α/β) [1]. It also behaves as a stem cell growth factor 
receptor (c-kit) that blocks tumor growth and ceases angiogenesis 
[2]. It has been approved for soft tissue sarcoma and also active in 
ovarian cancer [3]. It is a second-generation multi targeted tyrosine 
kinase inhibitor against vascular endothelial growth factor receptor 
targets the angiogenesis pathway that facilitates the formation of 
tumor blood vessel for tumor survival and growth [4]. Few 
analytical methods were reported for the determination of 
Pazopanib hydrochloride by UV [5], HPLC [6-7] in bulk as well as in 
tablets and an LC-MS/MS [8] method in mouse plasma and brain 
tissue homogenate.  
The presence of impurities in drug substance can have a significant 
impact on the quality, safety and efficacy Literature survey reveals 
that no reference exists for the quantitative determination and 
characterization of process impurities of PBH drug substance. 
Hence, it was felt necessary to develop an accurate, rapid, selective 
and sensitive RP-HPLC method for the determination of PBH and its 
process impurities. The newly developed method was validated as 
per ICH guidelines [9-11]. The newly identified process related 
impurities along with PBH drug substance have been isolated and 
characterized by Mass spectrometry. The two process impurities 
were identified with the help of NMR technique. 
MATERIALS AND METHODS 
Chemicals and reagents  
Potassium dihydrogen orthophosphate and orthophosphoric acid 
AR grade, Methanol HPLC grade (Merck Speciality Chemicals, India) 
and Water (Milli-Q water purification system, Millipore Synergy, 
France) were used. Pazopanib hydrochloride drug substance and 
process related compounds 5-amino-2-methyl benzene 
sulphonamide [PBHRC01] and N-(2-chlorophyrimidin-4-yl) N-2,3-
trimethyl-2H-indazol-6-amine [PBHRC02] were obtained from 
Synthetic Division of Ogene Systems Private Ltd, Hyderabad, India. 
Instrument 
The HPLC analysis was carried out on Shimadzu HPLC system 
(Shimadzu, Kyoto, Japan) with two LC-20AD separation modules, 
and SPD-20A UV detector were used. The chromatographic and 
integrated data were recorded using LC solution data acquisition 
software. An electronic analytical weighing balance (0.1 mg 
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491                 Vol 8, Issue 4, 2016 
Babu et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 4, 97-102 
 
98 
sensitivity, Shimadzu AY 220), digital pH meter (DELUX model 101), 
a Sonicator (Sonica, model 2200 MH)  
Methods 
Chromatographic conditions 
The main target of this study was to develop an RP-HPLC method to 
get fine resolutions between PBH and its process related impurities. 
Better results were obtained by employing a Zorbax RP18, (50 
mm×4.6 mm, 5.0 µm) column with buffer: methanol in the ratio 
(16:84) and adjusting the pH to 3.0 with orthophosphoric acid. The 
mobile phase was set at a flow rate of 0.8 ml/min and the volume 
injected was 10μl for every injection. The detection wavelength was 
set at 215 nm.  
Preparation of buffer 
2.04g of potassium dihydrogen orthophosphate was taken into 1000 
ml volumetric flask and dissolved to make 0.015M solution by 
diluting up to the mark with water. pH of the solution was adjusted 
to 3.0 with orthophosphoric acid. It is degassed and filtered through 
0.45 µm membrane filter. 
Standard preparation 
50 mg of Pazopanib HCl was accurately weighed and transferred 
into a 100 ml volumetric flask, dissolved and diluted up to the mark 
with diluent.(0.5 mg/ml solution) 
Impurities blend 
7.5 mg of each of the related compounds PBHRC01 and PBHRC02 
were weighed accurately and transferred into a 100 ml volumetric 
flask and diluted up to the mark with diluents. 
1.0 ml of the above solution was transferred into a 100 ml 
volumetric flask and diluted up to the mark with diluents, i.e., 0.15 
%of each impurity with respect to the test concentration. 
Method validation 
The optimized method was validated as per ICH guidelines. The 
validation parameters include specificity, limit of detection, and limit 
of quantification, accuracy, precision, linearity and robustness. 
Specificity 
Specificity is the ability to assess the analyte unequivocally in the 
presence of components which may be expected to be present. For 
this purpose, the sample of PBH was spiked with its impurities at a 
concentration of 0.03 mg/ml w. r. t. PBH concentration of 0.5 mg/ml. 
Detection limit and Quantitation limit  
Both DL and QL were evaluated based on standard deviation of the 
response and slope using the linearity curve.  
The formula used for DL and DQ were 3.3  σ/S and 10σ/S 
respectively, whereby σ is the standard deviation of the response 
while S is the slope of the calibration curve. 
Precision 
The repeatability expresses the precision under the same operating 
conditions over a short interval of time. It expresses the closeness of 
agreement between a series of measurements obtained from 
multiple sampling of the same homogeneous sample. System 
precision was performed by six replicate injections of PBH at 
specification level i.e. 0.03 mg mL-1
Accuracy 
 impurities spiked with respect to 
0.5 mg/ml PBH and the relative standard deviation was found. The 
precision of the method was determined by analyzing a sample of 
PBH with process impurities at 100 % of the specification limit. PBH 
spiked with process impurities for six times at the specification limit 
by different analysts, different instruments using different columns 
on different days to assess the intermediate precision. 
The study of the accuracy of PBH and its process impurities for 
quantification was carried out in triplicate at 3µg/ml (LOQ), 15 
µg/ml, 30 µg/ml and 45 µg/ml with respect to specification level viz 
30 µg/ml. 
Linearity 
Linearity test solutions for related compounds were prepared 
individually by diluting the stock solution at six concentration 
levels in the range of LOQ to 150 % of the specification level viz. 
0.15 %. Tests were carried out on three consecutive days in the 
same concentration range and % RSD value for slope, Y-intercept 
and correlation coefficient of the calibration curve were 
calculated. 
Robustness 
Robustness of the assay method was studied by introducing small 
changes in the chromatographic conditions which included mobile 
phase flow rate (±0.2 ml/min), pH (±0.2) and column temperature 
(±2 °C). 
RESULTS AND DISCUSSION  
Method development 
The main target of this study was to develop an RP-HPLC method to 
get fine resolutions between PBH and its process related impurities. 
Better results were obtained by employing a Zorbax RP18, (50 
mm×4.6 mm, 5.0 µm) column and adjust the pH to 3.0 with 
orthophosphoric acid. Finally, the experiment was preceded with 
the chromatographic conditions mentioned above. The impurities 
were well resolved from PBH with good peak shapes. 
 
 
Fig. 2: Blend chromatogram for impurities spiked to Pazopanib Hydrochloride drug substance 
Babu et al. 




The newly developed method was validated as per ICH guidelines 
for specificity, limit of detection, limit of quantification, sensitivity, 
linearity, precision, accuracy, and robustness. 
Specificity 
Specificity was established by injecting samples of PBH spiked with 
its impurities at a concentration of 0.03 mg/ml w. r. t. PBH 
concentration of 0.5 mg/ml. It is evident from fig.2 that the 
impurities were well resolved from each other and PBH, which 
indicated the specificity of the method. 
Detection limit and quantitation limit  
Detection limit and Quantitation Limit were determined by getting 
S/N ratio 3:1 and 10:1 respectively, after performing a series of 
diluted injections of PBHRC01 and PBHRC02 impurities with known 
concentration. The detection limits (LOD) were about 0.0061 and 
0.0062 mg/ml and quantitation limit (LOQ) were about 0.024 and 0.021 
mg/ml of PBH concentration i.e. 0.5 mg/ml were given in table 1. 
Precision 
System precision was determined by analyzing six replicate 
injections for PBH at specification level i.e. 0.03 mg/ml impurities 
spiked with respect to 0.5 mg/ml PBH and the relative standard 
deviation was found to be 0.78 %, 0.29 %, and 1.38 %respectively. 
The precision was checked by injecting 0.03 mg/ml of impurities 
from individual preparations with respect to 0.5 mg/ml of PBH. The 
% RSD of peak area for each impurity was reported in table 2. 
Precision at LOQ was also determined by injecting individual 
preparations of PBH spiked at LOQ level of its impurities. The 
intermediate precision of the method was also verified on six 
different days in the same laboratory using the specification and 
LOQ levels. Assay method precision was evaluated by carrying out 
independent assays of a test sample of PBH at 0.5 mg/ml, against a 
qualified reference standard. 
 
Table 1: Detection limit and Quantitation limit for Pazopanib hydrochloride process related impurities 
Parameter PBHRC-01 (mg/ml) PBHRC-02 (mg/ml) 
LOD 0.0061 0.0062 
LOQ 0.024 0.021 
 
Table 2: Precision data of peak areas for Pazopanib Hydrochloride process impurities 
Injection No PBH PBHRC01 PBHRC02 
1 9026 6161 9709 
2 8990 6155 9817 
3 9046 6161 9475 
4 9031 6175 9761 
5 9130 6190 9855 
6 9175 6200 9725 
Average area 9066 6174 9724 
SD 70.68 18.06 133.72 
 %RSD 0.78 0.29 1.38 
 
Table 3: Accuracy data for PBHRC01 and PBHRC02 
Conc PBHRC01 PBHRC02 
 %added  %found  %recovery Average  %added  %found  %recovery Average 
LOQ Level 0.020 0.0196 98.0 98 0.197 0.187 94.9 94.7 
0.020 0.0196 98.0 0.197 0.186 94.4 
0.020 0.0196 98.0 0.197 0.87 94.0 
50 % 0.100 0.100 100.0 99.3 0.098 0.097 99.0 98.7 
0.100 0.200 99.5 0.098 0.097 99.0 
0.100 0.200 99.0 0.098 0.096 98.0 
100 % 0.200 0.199 99.5 99 0.197 0.194 98.5 98.5 
0.200 0.198 99.0 0.197 0.194 98.5 
0.200 0.197 98.5 0.197 0.194 98.5 
150 % 0.300 0.294 98 97.7 0.2950.3 0.29 98.3 98.3 
0.300 0.292 97.3 0.295 0.289 98 
0.300 0.293 97.7 0.295 0.291 98.6 
 
Accuracy 
The % recovery of the PBH impurities ranged from 97.3 to 100 % for 
PBHRC01 and 94.0 %to 99.0 %for PBHRC02 respectively, which 
shows that the developed method is accurate and suitable for its 
intended use. The results were given in table 3. 
Linearity 
Linearity test solutions for related compounds were prepared 
individually by diluting the stock solution at six concentration levels 
in the range of LOQ to 150 % of the specification level viz. 0.15 %. 
Tests were carried out on three consecutive days in the same 
concentration range and % RSD value for slope, Y-intercept and 
correlation coefficient of the calibration curve were calculated. The 
peak area versus concentration data was subjected to least-squares 
linear regression analysis and the results are summarized in table 4. 
The linearity plots were as shown in fig 3 and fig 4 for PBHRC01 and 
PBHRC02 respectively. 
Robustness 
Robustness of the assay method was studied by introducing small 
changes in the chromatographic conditions which included mobile 
phase flow rate (±0.2 ml/min), pH (±0.2) and column temperature 
(±2 °C). The results revealed that these alterations did not have any 
impact on the chromatographic performance. The results were given 
in table 5. 
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Table 4: Linearity data for PBHRC01 and PBHRC02 
 %of level PBHRC01 PBHRC02 
Conc.(mg/ml) Peak area Conc.(mg/ml) Peak area 
LOQ 0.102 6174 0.098 9724 
50 0.510 30880 0.492 50576 
75 0.764 45965 0.738 75828 
100 1.019 60671 0.985 100568 
125 1.274 77012 1.231 126866 
150 1.529 90528 1.477 152803 
(R) 0.9998 1.0000 
Slope 59410.93 103518.2 
Intercept 401.9967 -566.628 
 
 
Fig. 3: Linearity plot for PBHRC-01 
 
Fig. 4: Linearity plot for PBHRC-02 
 
Table 5: Robustness data for PBHRC-01 and PBHRC-02 
Parameter PBHRC-01 PBHRC-02 
Variation  %RSD Theoretical plates(N) Asymmetry Variation  %RSD Theoretical plates(N) Asymmetry 
Flow 
(ml/min) 
0.6 1.12 14235 0.99 0.6 1.11 24134 1.05 
0.8 1.18 15421 1.01 0.8 1.13 25312 1.04 
1.0 1.05 14834 1.03 1.0 1.17 24147 1.03 
Temperature 
( °C) 
38 1.14 17647 0.99 38 2.74 23147 0.99 
40 0.98 18924 1.02 40 2.15 21457 1.01 
42 2.12 18437 1.02 42 2.14 22467 1.05 
pH 2.8 1.42 19017 1.01 2.8 1.08 25134 1.01 
3 1.14 18345 1.01 3.1 1.47 24456 1.02 
3.2 1.45 18754 1.02 3.2 1.43 23147 1.03 
 
Solution stability 
The solution stability of PBH and its impurities in diluent was 
determined by leaving 0.15 % spiked sample solution in a tightly 
capped volumetric flask at room temperature for 48 h and 
measuring the amounts of the compounds for every 12 h and 
comparing the results with those obtained from freshly prepared 
solution. The mobile phase was prepared at the beginning of the study 
period and was not changed during the experiment. All the samples 
were found to be stable up to 48 h. The results are shown in table 6. 
 
Table 6: Solution stability data for Pazopanib Hydrochloride and its process impurities 
Compound Peak area 
Initial 12 h 24 h 36 h 
PBHRC01 65124 64387 66472 64387 
PBHRC02 110234 100234 105473 115463 
PBH 75134 74321 75214 74987 
 
Characterization 
PBH process related impurities were characterized by Mass 
Spectrometry to identify the mass of the two process impurities. The 
structural elucidation was performed with the help of NMR 
spectroscopic technique. 
Mass spectrometry (LC–MS) studies  
Quattro Micro TM
Mass spectral data identified the structures of process impurities 
of PBH as PBHRC01 and PBHRC02, which were reported in fig 5. 
A [M+H]
API mass spectrophotometer (Waters-Micro mass, 
Manchester, UK), was used to perform Mass Spectral (MS) analysis 
using electron spray ionization at a voltage of 4.0 KV at a desolvation 
gas temperature of 100 °C and a source temperature of 400 °C. The 
desolvation gas flow was fixed at 450 l/hr.  
+ molecular ion peak was identified in positive ionization 
mode at m/z 209.12 corresponding to PBHRC01 and another 
[M+H]+ was observed in positive ionization at 310.11 
corresponding to PBHRC02. 
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Fig. 5: Structures of Pazopanib impurities 
 
Table 7: NMR data for NMR data for Pazopanib Hydrochloride related compound 01 
Carbon No Multiplicity 1H NMR (ppm) 
7 (3H) S 2.494 
4(1H) Dd 6.768-6.803 
3 (1H) D 7.036-7.063 
6 (1H) D 7.323-7.331 
 
Table 8: NMR data for NMR data for Pazopanib 
Carbon No Multiplicity 1H NMR (ppm) 
8 (3H) S 2.648 
10 (3H) S 3.531 
9 (3H) S 4.130 
5’ D  (1H) 6.167-6.188 
5 (1H) Dd 6.807-6.842 
7 (1H) D 7.470-7.474 
4 (1H) Dd 7.643-7.672 
6’ D  (1H) 7.824-7.845 
 
NMR spectroscopic studies 
Proton NMR experiments were performed using 300 MHz FT-NMR 
spectrometer (Bruker, BioSpin Corporation, Billerica, MA, USA) in 
CDCl3 at 25 °C temperature. The chemical shifts of protons were 
reported on the δ scale in ppm relative to TMS and CDCl3 
respectively. The 1H NMR spectrum of PBHRC01 fig. 6, exhibits a 
characteristic amino proton (s–2H) and (s–2H) chemical shift at 
6.768-6.803 and 5.418-5.347. The 1
 
H NMR spectrum of PBHRC02 fig. 
7 exhibits a characteristic 3-methyl proton (3s–9H) chemical shift at 
2.648, 3.531 and 4.130. The NMR data for the two process impurities 
were given in table 7 and table 8. 
Hydrochloride related to compound 02 
 
Fig. 6: NMR spectrum of NMR data for Pazopanib Hydrochloride related compound 01 
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Fig. 7: NMR spectrum of NMR data for Pazopanib Hydrochloride related compound 02 
 
CONCLUSION 
In this study, two new process impurities of Pazopanib HCL drug 
substance were determined and characterized by newly developed 
RP-HPLC method and identified using LC–MS technique. Proposed 
structures of these impurities were confirmed by structural 
elucidation using NMR techniques. The HPLC method was validated 
as per ICH guidelines. Newly developed HPLC method was found to 
be simple, sensitive, and selective. It was found to have an excellent 
resolution for the two impurities and PBH drug substance indicating 
high sensitivity and selectivity of the validated method. 
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